Intravenous administration of piceatannol, an arginase inhibitor, improves endothelial dysfunction in aged mice
The Korean Journal of Physiology and Pharmacology
; : 83-90, 2017.
Article
Dans En
| WPRIM
| ID: wpr-728254
Responsable en Bibliothèque :
WPRO
ABSTRACT
Advanced age is one of the risk factors for vascular diseases that are mainly caused by impaired nitric oxide (NO) production. It has been demonstrated that endothelial arginase constrains the activity of endothelial nitric oxide synthase (eNOS) and limits NO generation. Hence, arginase inhibition is suggested to be vasoprotective in aging. In this study, we examined the effects of intravenous injection of Piceatannol, an arginase inhibitor, on aged mice. Our results show that Piceatannol administration reduced the blood pressure in aged mice by inhibiting arginase activity, which was associated with NO production and reactive oxygen species generation. In addition, Piceatannol administration recovered Ca²⁺/calmodulin-dependent protein kinase II phosphorylation, eNOS phosphorylation and eNOS dimer stability in the aged mice. The improved NO signaling was shown to be effective in attenuating the phenylephrine-dependent contractile response and in enhancing the acetylcholine-dependent vasorelaxation response in aortic rings from the aged mice. These data suggest Piceatannol as a potential treatment for vascular disease.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Phosphorylation
/
Arginase
/
Protein kinases
/
Maladies vasculaires
/
Vasodilatation
/
Pression sanguine
/
Vieillissement
/
Facteurs de risque
/
Espèces réactives de l'oxygène
/
Nitric oxide synthase type III
Type d'étude:
Etiology_studies
/
Risk_factors_studies
Limites du sujet:
Animals
langue:
En
Texte intégral:
The Korean Journal of Physiology and Pharmacology
Année:
2017
Type:
Article